

# Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

NCT06895733

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Tianjin Medical University Second Hospital
<b>Enrollment</b>	65 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Voluntarily join this study and sign an informed consent form;
- e 18years old;
- Patients with metastatic solid tumors diagnosed by histology or cytology; Queue 1:11q13 co amplified or FGFR1/FGFR2 amplified urothelial carcinoma Queue 2: Head and neck squamous cell carcinoma co amplified in 11q13 region Queue 3:11q13 co amplified other solid tumors
- Disease progression or intolerable toxicity confirmed by imaging during or after treatment with at least two standard treatment regimens in the past;
- According to RECIST 1.1, there must be at least one measurable lesion;
- ... and 6 more (see full listing online)

### Exclusion (21)

- Known history or evidence of interstitial lung disease or active non infectious pneumonia;
- Known to have central nervous system metastases;
- Within the past 5 years or simultaneously with other malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ);
- Suffering from hypertension and unable to achieve good control with antihypertensive medication (systolic blood pressure e 140 mmHg or diastolic blood pressure e 90 mmHg); Allow the above parameters to be achieved through the use of antihypertensive therapy; Previously experienced hypertensive crisis or hypertensive encephalopathy;
- There are uncontrolled clinical symptoms or diseases of the heart, such as: (1) NYHA grade 2 or above heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention, (5) QTc>450ms (male); QTc>470ms (female);
- ... and 16 more (see full listing online)

## Locations (1 total)

---

Tianjin Medical University Second Hospital, Tianjin, Tianjin Municipality, China

---

<https://clinicaltrials.gov/study/NCT06895733>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.